An observational study in Heart Failure, Valvular Heart Diseases and Atrial Fibrillation (AF), sponsored by Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC). Enrolling by invitation at 1 site in Spain. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Heart Failure with a site in Spain — 76 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Spain.
Among the 342 studies in Heart Failure with a site in Spain, this one is the 37th largest by planned enrollment of the 78 observational ones that give a count, is one of 19 that started in 2023, is one of 78 observational ones, reaches primary completion later than 32 of the 98 other live ones, and was the 319th registered.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →76 of the 342 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:
AnaCardio AB · Sites in Spain, United States, Bulgaria and 5 more countries
Ages 18–85
Carolina Ortiz Cortes · Sites in Spain
Ages 18+ · Women only
AstraZeneca · Sites in Spain, United States, Argentina and 29 more countries
Ages 18+
AstraZeneca · Sites in Spain, United States, Germany and 2 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Spain, Austria, Czechia and 4 more countries
Ages 18–99
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 15 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 42 · Phase 3 78 · Phase 4 24
First in 1983; this study’s year is marked. 19 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 294 across the 263 interventional studies, 500 across the 78 observational. Of the 213 that completed or were terminated, 86 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
190 of 342 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC) as lead sponsor.
Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC) has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
31 of the studies in Heart Failure with a site in Spain that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07008365Phase 3Instituto de Investigación Sanitaria AragónThe Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure | 2026-11-30 |
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT06712030Phase 3Puerta de Hierro University HospitalEffect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction | 2027-04 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add all 31 to your calendar (.ics) → With an account.
Among the 342 studies in Heart Failure with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Observational Study on the Validation of Family Doctors' Training in Echocardiography
The Catalan Society of Family and Community Medicine (CAMFiC) developed a structured training program for Family Physicians in focused cardiac ultrasound (FoCUS). This study evaluates GP FoCUS performance against comprehensive echocardiography and assesses training competence.
Developed between September 2023 and November 2025 (92 hours total, including 70 hours supervised practice), participants perform FoCUS on patients with suspected cardiac pathology. The study measures concordance between GP FoCUS and cardiologist echocardiography, and evaluates FoCUS integration into primary care pathways to enhance diagnostic capacity for common cardiac conditions.
ACKGROUND \& JUSTIFICATION Cardiovascular disease generates long cardiology waiting lists in Spain (>90 days echocardiography). Elderly patients discharged from hospital require cardiac follow-up in primary care, but Family Medicine residency (MIR) excludes point-of-care ultrasound (POCUS) training. This gap limits GP triage capacity for common cardiac pathology.
The Catalan Society of Family and Community Medicine (CAMFiC), in collaboration with the Catalan Society of Cardiology (SCC), developed a structured FoCUS training program (2022, 92 hours total: 18h theory + 4h workshop for cardiac views + 70h supervised hospital practice) to empower primary care physicians.
HYPOTHESIS
Primary Hypotheses:
This training program achieves ≥80% concordance between GP-performed FoCUS and cardiologist-performed standard echocardiography on predefined cardiac parameters (κ≥0.6).
Secondary Hypotheses:
STUDY OVERVIEW Prospective observational study (CEIm IDIAP 23/072-P). 46 CAMFiC GPs perform FoCUS on consecutive adult patients (>18 years) with clinical cardiac indication during primary care visits, followed by cardiologist echocardiography confirmation. Data captured via REDCap eCRF.
See Outcomes, Eligibility Criteria, and Arms/Interventions for specific measures, criteria, and procedures.
PHASES
CLINICAL IMPACT Reduces time-to-diagnosis, shortens cardiology waiting lists, enables primary care triage of common cardiac conditions, cost-effective, scalable model.
PROTOCOL AVAILABILITY Full protocol available upon request from IDIAP Jordi Gol Primary Care Research Institute.
See structured sections (Outcomes, Eligibility Criteria, Arms/Interventions) for specific measures, criteria, and procedures.
The study population will consist of:
Inclusion criteria for professionals in the training program are:
Willing and able to complete all training and study procedures. Exclusion criteria: Not meeting any inclusion criterion.
The inclusion criteria for patients are:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort of GPs: Board-certified Family and Community Medicine specialists in Catalonia who will complete a structured FoCUS training programme and participate in a validation study. Intervention of interest: FoCUS training (online theory + supervised hands-on practice, including simulator assessment) followed by routine FoCUS use in primary care with data capture in REDCap and paired comparison with cardiologist echocardiography. Inclusion criteria: Family and Community Medicine specialist; CAMFiC member; workplace access to an ultrasound device suitable for FoCUS; commitment to complete the programme. Exclusion criteria: Not meeting any inclusion criterion.
Other: Cohort of GPs: Training program
Cohort of Patients: Individuals aged \>18 years who require cardiac imaging for any clinical indication in routine care at a site where a participating GP works. Intervention of interest: A FoCUS assessment performed by the trained GP as part of usual clinical care; no additional study tests or follow-up visits. Sampling: Non-random, consecutive/clinician-driven recruitment based on routine clinical need and medical judgment. Exclusion criteria: Refusal to participate (no written informed consent) and severe mental illness or significant cognitive impairment preventing informed consent.
Diagnostic Test: Cohort of patients
1. Accredited curriculum: 18 hours of online theory (2.7 CCFCPS credits) with a mandatory 20-item MCQ assessing knowledge and image interpretation. 2. Structured, supervised scanning volume: 4-hour hands-on introductory session on core cardiac views using healthy volunteers, followed by 70 hours of supervised clinical training with a hospital cardiologist, including a predefinied target of 60 FoCUS examinations per GP.
Eligible patients are those seen in routine primary care by participating GPs who, based on usual clinical judgment, need an echocardiographic assessment. In these cases, the GP will perform a FoCUS scan as part of the consultation and record a standard set of variables in the study eCRF. When the patient subsequently undergoes a comprehensive echocardiography in cardiology, both assessments (GP FoCUS and cardiology echocardiography) will be paired to evaluate agreement. No additional tests or extra study visits are required beyond usual care.
Agreement between GP-performed FoCUS and cardiologist-performed standard echocardiography.
Agreement between GP-performed FoCUS and cardiologist-performed standard echocardiography on key cardiac parameters: left ventricular systolic function (preserved vs. reduced), cavity sizes (normal vs. dilated), and significant valve abnormalities (none vs. moderate-severe). Additional parameters include pericardial effusion and IVC dilation. Measured by weighted kappa coefficient comparing blinded independent interpretations of the same patients. Higher κ = better agreement. Clinical competency threshold κ ≥ 0.6 (substantial agreement). Unit of measure: Weighted kappa coefficient (0-1)
Time frame: Diagnostic agreement assessment in real-world clinical practice following training completion (2024-2027 recruitment period).
GPs knowledge and competence after FoCUS training
Change from baseline in 20-item MCQ knowledge score + % practical competencies checklist + simulator pass rate, assessing FoCUS training effectiveness for GPs (Objective 1).
Time frame: Training completion (6-8 months post-enrolment)
FoCUS routine integration in clinical practice
Proportion of trained GPs regularly using FoCUS (≥1/week) in primary care consultations, assessed by participant survey at end of recruitment (Objective 3).
Time frame: Following completion of recruitment (December 2027), a survey will be conducted among the 46 family physicians who have participated in this training program to assess the proportion regularly applying FoCUS (≥1/week) in routine primary care consultation
FoCUS indications and abnormalities documented.
Frequency of predefined indications (dyspnea, heart murmur, suspected heart failure, cardiac arrhythmia) and key abnormalities documented during routine FoCUS use (Objective 4).
Time frame: Documentation analysis of FoCUS performed during study period for clinical indications and documented key abnormalities: first half of 2028 (January-June 2028), following recruitment completion and REDCap data extraction.
Time from FoCUS triage to specialist care
Time elapsed from the detection of significant cardiac findings using FoCUS to care by a specialist/echocardiography in general practitioners trained in FoCUS versus standard care, evaluating the benefits of triage and accelerated care pathways (hypothesis 6+8).
Time frame: Real-world implementation (2024-2027)
Programme acceptability and satisfaction
Satisfaction scores (1-5 Likert scale) from patients, GPs, and cardiologists regarding FoCUS programme acceptability and usability (Objective 7).
Time frame: Programme completion (2027)
Plan to share: No — Patient data will be collected in a pseudonymised format in REDCap, a secure platform for clinical research data management. Access to the dataset will be restricted to authorised members of the research team and used solely to address the study objectives. Data handling will comply with applicable data protection regulations, safeguarding confidentiality throughout the study and subsequent analyses. There is no plan to share individual participant data (IPD) outside the study team.
Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 39 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.